External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Date 2025 Jan 21

PMID 39836421

Authors

Cherie Lin

Jie Su

Alison J Wu

Neil Lin

Madison-Shira Hossack

Wei Shi

Wei Xu

Fei-Fei Liu

Jennifer Y Y Kwan

Affiliations

Soon will be listed here.

Abstract

Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.

Objective: To investigate the external validity of a previously reported 5-factor model by applying it to an independent cohort of patients with breast cancer.

Design, Setting, And Participants: This prognostic study collected data on a longitudinal cohort of patients with predominantly early-stage breast cancer treated with curative intent at the Princess Margaret Cancer Centre in Toronto, Canada between February 1, 2010, and July 31, 2014, with a median (IQR) follow-up of 4.3 (2.4-7.6) years. The 5 factors (age, body mass index, breast density, nodal burden, and use of axillary lymph node dissection [ALND]) were used as input into the established regression-based model. The analysis was performed from July 2 through August 29, 2024.

Exposure: Lymphedema after breast cancer treatment.

Main Outcomes And Measures: Lymphedema-free survival (LFS) was analyzed using Kaplan-Meier analysis, and sensitivity, specificity, and accuracy performance metrics of predicting breast cancer-related lymphedema were calculated.

Results: A total of 101 female patients (median [IQR] age, 54.8 [48.8-62.3] years) were included in the analysis. These patients had localized or locoregional breast cancer treated with primary lumpectomy (90 [89%]) or mastectomy (11 [11%]); 75 (74%) had no axillary biopsy or sentinel lymph node biopsy; 26 (26%) had undergone ALND; and 38 (38%) had received chemotherapy, 101 (100%) received radiotherapy, and 64 (63%) received hormone therapy. Kaplan-Meier analysis showed a 2-year LFS of 97.5% (95% CI, 94.0%-100.0%) vs 65.0% (95% CI, 47.1%-89.7%) for the low- vs high-risk groups as defined by the 5-factor model (P < .001). The model sensitivity was 0.83 (95% CI, 0.52-0.98), specificity was 0.89 (95% CI, 0.80-0.94), and accuracy was 0.88 (95% CI, 0.80-0.94) for predicting breast cancer-related lymphedema.

Conclusions And Relevance: These findings validate the performance of a 5-factor risk model for its prediction of 2-year LFS. Future clinical translation of this model can help with identifying patients at the highest risk of breast cancer-related lymphedema to facilitate closer surveillance and/or preventive management to improve health outcomes and quality of life.

References

Hara Y, Otsubo R, Shinohara S, Morita M, Kuba S, Matsumoto M . Lymphedema After Axillary Lymph Node Dissection in Breast Cancer: Prevalence and Risk Factors-A Single-Center Retrospective Study. Lymphat Res Biol. 2022; 20(6):600-606. PMC: 9810350. DOI: 10.1089/lrb.2021.0033. View

Jiang X, Tian W, Nicolls M, Rockson S . The Lymphatic System in Obesity, Insulin Resistance, and Cardiovascular Diseases. Front Physiol. 2019; 10:1402. PMC: 6868002. DOI: 10.3389/fphys.2019.01402. View

Heagerty P, Zheng Y . Survival model predictive accuracy and ROC curves. Biometrics. 2005; 61(1):92-105. DOI: 10.1111/j.0006-341X.2005.030814.x. View

Ginsburg O, Bray F, Coleman M, Vanderpuye V, Eniu A, Kotha S . The global burden of women's cancers: a grand challenge in global health. Lancet. 2016; 389(10071):847-860. PMC: 6191029. DOI: 10.1016/S0140-6736(16)31392-7. View

Conroy S, Butler L, Harvey D, Gold E, Sternfeld B, Greendale G . Metabolic syndrome and mammographic density: the Study of Women's Health Across the Nation. Int J Cancer. 2010; 129(7):1699-707. PMC: 3610563. DOI: 10.1002/ijc.25790. View

Wang L, Chen H, Li Y, Wang H, Liu N, Yu M . Body mass index increases the risk of breast cancer-related lymphedema at 6-18 months after surgery: a retrospective study. Support Care Cancer. 2023; 31(5):278. DOI: 10.1007/s00520-023-07721-7. View

Habibzadeh F, Habibzadeh P, Yadollahie M . On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016; 26(3):297-307. PMC: 5082211. DOI: 10.11613/BM.2016.034. View

Nathanson S, Detmar M, Padera T, Yates L, Welch D, Beadnell T . Mechanisms of breast cancer metastasis. Clin Exp Metastasis. 2021; 39(1):117-137. PMC: 8568733. DOI: 10.1007/s10585-021-10090-2. View

Yee Kwan J, Famiyeh P, Su J, Xu W, Kwan B, Jones J . Development and Validation of a Risk Model for Breast Cancer-Related Lymphedema. JAMA Netw Open. 2020; 3(11):e2024373. PMC: 7658732. DOI: 10.1001/jamanetworkopen.2020.24373. View

10.

Shi W, Misra S, Li M, Su J, Chong L, McCuske M . Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy. JNCI Cancer Spectr. 2020; 4(5):pkaa037. PMC: 7583146. DOI: 10.1093/jncics/pkaa037. View

11.

Baratloo A, Hosseini M, Negida A, El Ashal G . Part 1: Simple Definition and Calculation of Accuracy, Sensitivity and Specificity. Emerg (Tehran). 2015; 3(2):48-9. PMC: 4614595. View

12.

DiSipio T, Rye S, Newman B, Hayes S . Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013; 14(6):500-15. DOI: 10.1016/S1470-2045(13)70076-7. View

13.

Greene A, Grant F, Slavin S . Lower-extremity lymphedema and elevated body-mass index. N Engl J Med. 2012; 366(22):2136-7. DOI: 10.1056/NEJMc1201684. View

14.

Yaghoobi Notash A, Yaghoobi Notash A, Omidi Z, Haghighat S . Prediction of lymphedema occurrence in patients with breast cancer using the optimized combination of ensemble learning algorithm and feature selection. BMC Med Inform Decis Mak. 2022; 22(1):195. PMC: 9310496. DOI: 10.1186/s12911-022-01937-z. View

15.

Guo S, Zeller C, Chumlea W, Siervogel R . Aging, body composition, and lifestyle: the Fels Longitudinal Study. Am J Clin Nutr. 1999; 70(3):405-11. DOI: 10.1093/ajcn/70.3.405. View

16.

Cormier J, Askew R, Mungovan K, Xing Y, Ross M, Armer J . Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010; 116(22):5138-49. DOI: 10.1002/cncr.25458. View

17.

Bevilacqua J, Kattan M, Changhong Y, Koifman S, Mattos I, Koifman R . Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer. Ann Surg Oncol. 2012; 19(8):2580-9. DOI: 10.1245/s10434-012-2290-x. View

18.

Safari S, Baratloo A, Elfil M, Negida A . Evidence Based Emergency Medicine Part 2: Positive and negative predictive values of diagnostic tests. Emerg (Tehran). 2015; 3(3):87-8. PMC: 4608333. View

19.

Barraclough H, Simms L, Govindan R . Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol. 2011; 6(6):978-82. DOI: 10.1097/JTO.0b013e31821b10ab. View

20.

Soran A, Menekse E, Girgis M, DeGore L, Johnson R . Breast cancer-related lymphedema after axillary lymph node dissection: does early postoperative prediction model work?. Support Care Cancer. 2015; 24(3):1413-9. DOI: 10.1007/s00520-015-2933-0. View